NASDAQ:DNLI - Denali Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$21.55 +0.55 (+2.62 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$21.00
Today's Range$20.52 - $21.56
52-Week Range$12.32 - $25.79
Volume255,949 shs
Average Volume335,283 shs
Market Capitalization$2.05 billion
P/E Ratio-3.66
Dividend YieldN/A
BetaN/A
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.29 per share

Profitability

Net Income$-88,180,000.00

Miscellaneous

Employees130
Market Cap$2.05 billion
OptionableOptionable

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc (NASDAQ:DNLI) posted its earnings results on Thursday, November, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.13. The company earned $1.20 million during the quarter, compared to analysts' expectations of $3 million. View Denali Therapeutics' Earnings History.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Denali Therapeutics.

What price target have analysts set for DNLI?

2 Wall Street analysts have issued twelve-month price objectives for Denali Therapeutics' stock. Their forecasts range from $25.00 to $26.00. On average, they anticipate Denali Therapeutics' share price to reach $25.50 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.

What is the consensus analysts' recommendation for Denali Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.

What are Wall Street analysts saying about Denali Therapeutics stock?

Here are some recent quotes from research analysts about Denali Therapeutics stock:
  • 1. According to Zacks Investment Research, "Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. " (1/3/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month PT of $25/share of DNLI after attending Denali’s R&D Day. We believe the company is approaching neurodegenerative diseases through rigorous therapeutic discovery and development, and we expect increasingly visible pipeline progress will enhance investor conviction over the next 12-18 months. The event provided a broad perspective on pipeline strategy that could address many of the historic challenges for neurodegenerative disease drug development. Our focus is currently on the small molecule programs for DNL201 in Parkinson’s disease (PD) and DNL747 in Alzheimer’s disease (AD), ALS, and MS, which are the most advanced programs." (12/7/2018)

Has Denali Therapeutics been receiving favorable news coverage?

Media stories about DNLI stock have been trending very positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Denali Therapeutics earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are some of Denali Therapeutics' key competitors?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the folowing people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 42)
  • Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 45)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 58)
  • Mr. Steve E. Krognes, CFO, Principal Accounting Officer & Treasurer (Age 49)
  • Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 45)

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $21.55.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $2.05 billion. The company earns $-88,180,000.00 in net income (profit) each year or ($5.89) on an earnings per share basis. Denali Therapeutics employs 130 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is http://www.denalitherapeutics.com.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.


MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel